Lupin shares rise nearly 4% on plans to build manufacturing facility in Florida; what investors need to know

"With a projected cumulative investment of $250 million, including research & development, infrastructure, and capital expenditures over a five-year period, the new site will have the capacity to accommodate the production of more than 25 critical respiratory medicines, including lifesaving albuterol inhalers for children with asthma and service members at home and overseas," Lupin said in its press release.

By strengthening domestic manufacturing and enhancing supply chain diversification, this critical project will enhance medicine security and strengthen Lupin’s position as a global respiratory leader. Locally, this will generate over 200 new long-term, skilled jobs by 2030 in Broward County, the company added.

The Coral Springs facility will anchor US production of critical respiratory therapies, diversify the supply chain, and ensure affordable, reliable access—from routine paediatric care to pandemic-scale demand. Lupin has acquired more than 5 acres of land to embark on this expansion of 70,000 square feet.

About Lupin

Lupin is one of the leading global pharmaceutical companies with products in over 100 markets and a strong U.S. footprint in respiratory care and complex generics. With its US headquarters in Naples, Florida, the company operates 15 manufacturing sites and seven research centres globally and employs more than 24,000 professionals.

Lupin: Recent update

Early in October, Lupin said it had launched a generic diabetes medication in the US market.

It has launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen in the US, the Mumbai-based drug maker said in a statement.

The product is bioequivalent to Novo Nordisk Inc.'s Victoza injection, it added.

It is indicated as an adjunct to diet and exercise to improve glycaemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

As per the IQVIA MAT data, the medication had an estimated annual sales of $350 million in the US.

"This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients," Lupin President of US Generics Spiro Gavaris said.